Results 11 to 20 of about 21,331 (238)
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies
Journal of Hematology & Oncology, 2021 B cell receptor (BCR) signaling is involved in the pathogenesis of B cell malignancies. Activation of BCR signaling promotes the survival and proliferation of malignant B cells.
Danling Gu +4 more
doaj +1 more source
Molecules, 2023 Bruton tyrosine kinase (BTK) is an essential enzyme in the signaling pathway of the B-cell receptor (BCR) and is vital for the growth and activation of B-cells.
Qi Zhang +3 more
doaj +1 more source
Медицинская иммунология, 2023 Bruton's tyrosine kinase (BTK) inhibitors represent a class of drugs that have demonstrated their efficacy and safety in patients with chronic lymphocytic leukemia and non-Hodgkin's lymphomas who were considered refractory to any previously used type of ...
Yu. S. Torshina +4 more
doaj +1 more source
Heliyon, 2023 Bruton's tyrosine kinase (BTK) is a protein involved in B-cell-receptor signaling and B-cell proliferation. The pathophysiology of several autoimmune diseases, such as pemphigus disorder, relies on the BTK signaling pathway.
Yekta Ghane +4 more
doaj +1 more source
Biomarker Research, 2022 The advent of BTK inhibitors has changed the treatment of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The first-in-class BTK inhibitor ibrutinib has shown remarkable therapeutic effects and manageable toxicities in ...
Jing Zhang +3 more
doaj +1 more source
Experimental Hematology & Oncology, 2023 Targeted therapy with Bruton tyrosine kinase (BTK) inhibitors have revolutionized the treatment of patients with various B-cell malignancies. BTK inhibitors such as ibrutinib, zanubrutinib, orelabrutinib, and acalabrutinib have shown good clinical ...
Yuqin Song +18 more
doaj +1 more source
Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review
Metabolism Open, 2021 Coronavirus disease 2019 (COVID-19) is first detected in December 2019 in Wuhan, China which is a new pandemic caused by SARS-COV-2 that has greatly affected the whole world.
Zemene Demelash Kifle
doaj +1 more source
Current Oncology, 2023 The most common forms of B-cell malignancy, non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), have seen a drastic shift in the treatment landscape over the last two decades with the introduction of targeted agents.
Shannon Nixon +3 more
doaj +1 more source
Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML [PDF]
, 2014 Pharmacological targeting of BTK using ibrutinib has recently shown encouraging clinical activity in a range of lymphoid malignancies. Recently we reported that ibrutinib inhibits human acute myeloid leukemia (AML) blast proliferation and leukemic cell ...
Bowles, Kristian M +6 more
core +8 more sources
Pharmaceuticals, 2023 Bruton’s tyrosine kinase (BTK) is a critical component in B-cell receptor (BCR) signaling and is also expressed in haematogenic and innate immune cells. Inhibition of BTK hyperactivity is implicated in B-cell malignancies and autoimmune diseases.
Asim Najmi +8 more
doaj +1 more source